BRISTOL-MYERS SQUIBB COMPANY Sales Revenue, Services, Net (Deprecated 2018-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Sales Revenue, Services, Net (Deprecated 2018-01-31) of $81.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueServicesNet · last filed 2018-10-25
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2018-09-30 was $81.00M, a 49.38% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $89.00M, a 35.04% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $69.00M, a 44.35% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was -$197.00M.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, net (deprecated 2018-01-31) for fiscal 2017 was $224.00M, a 133.33% increase from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, net (deprecated 2018-01-31) for fiscal 2016 was $96.00M, a 10.28% decline from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY sales revenue, services, net (deprecated 2018-01-31) for fiscal 2015 was $107.00M.
| Period end | Sales Revenue, Services, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-09-30 | $81.00M 10-Q · filed 2018-10-25 | $170.00M derived: sum of 2 quarters · filed 2018-10-25 | $239.00M 10-Q · filed 2018-10-25 | $42.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-06-30 | $89.00M 10-Q · filed 2018-07-26 | $158.00M 10-Q · filed 2018-07-26 | -$39.00M derived: sum of 3 quarters · filed 2018-07-26 | $121.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-03-31 | $69.00M 10-Q · filed 2018-04-26 | -$128.00M derived: sum of 2 quarters · filed 2018-04-26 | $32.00M derived: sum of 3 quarters · filed 2018-10-25 | $169.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-12-31 | -$197.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$37.00M derived: sum of 2 quarters · filed 2018-10-25 | $100.00M derived: sum of 3 quarters · filed 2018-10-25 | $224.00M 10-K · filed 2018-02-13 |
| 2017-09-30 | $160.00M 10-Q · filed 2018-10-25 | $297.00M derived: sum of 2 quarters · filed 2018-10-25 | $421.00M 10-Q · filed 2018-10-25 | |
| 2017-06-30 | $137.00M 10-Q · filed 2018-07-26 | $262.00M 10-Q · filed 2018-07-26 | ||
| 2017-03-31 | $124.00M 10-Q · filed 2018-04-26 | |||
| 2016-12-31 | $96.00M 10-K · filed 2018-02-13 | |||
| 2015-12-31 | $107.00M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |